CMIC Group is engaged in innovation-driven business that supports drug development.
As a member of the Group, SSI conducts business from the perspective of future medicine.
SSI is part of CMIC Group that established the first Contract Research Organization (CRO) in Japan. Based on a unique ‘Pharmaceutical Value Creator’ (PVC) business model, CMIC Group business extends broadly from its core CRO business to services associated with drug development, manufacturing, and marketing, in addition to in-house development of orphan drugs and diagnostics. This comprehensive capability serves as the backbone of SSI, and we actively collaborate with other affiliates to advance medical innovation in Japan.
